MAP3K1

mitogen-activated protein kinase kinase kinase 1

Explore in graph →CI-GENE-00011962HGNC:6848 ENSG00000095015 NCBI 4214 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
MAP2K4 loss-of-function Mutation + MAP3K1 Loss-of-Function MutationMAP2K4 MAP3K11
Selumetinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	submitted	EID12141 In this study, sensitivity to MEK inhibitors was evaluated in multiple cancer models harbouring MAP3K1 and MAP2K4 loss-of-function mutations. In in-vitro experiments, two breast cancer cell lines, MDA… (full text at CIViC) PMID 29795445 · Xue et al., 2018 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (139)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved139 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Breast Invasive Lobular Carcinoma (MSK, NPJ Precis Oncol 2024) ilc_msk_2023	unmapped	Ssm	1	25

Literature

Linked publications (0)

Data not yet available

No publication linked to this gene yet.